Vincristine-induced adverse events related to body weight in dogs treated for lymphoma
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17063 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Veterinary Internal Medicine, 2024. Verfasst von Keira E Sztukowski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Dog Diseases, Vincristine, Lymphoma, Body Weight. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Traditional dosing of chemotherapy drugs based on body surface area may overdose small dogs, leading to an increased frequency of adverse events (AEs). Hypothesis/Objectives Evaluate the frequency of hematologic and gastrointestinal AEs in dogs with newly diagnosed lymphoma treated with vincristine weighing ≤15 kg in comparison to dogs weighing >15 kg. We hypothesized that dogs weighing ≤15 kg would experience a higher frequency of AEs. Animals One hundred and thirty-eight dogs with newly diagnosed lymphoma were treated with vincristine.
Methods
A multicenter retrospective study reviewing hematologic data and medical record information. Complete blood counts were performed no more than 24 hours before vincristine administration and then between 4 and 8 days post-administration. Data were evaluated using logistic regression or ordinal logistic regression.
Results
Thirty-eight dogs weighing ≤15 kg and 100 dogs weighing >15 kg were included. The median vincristine dose for both groups was 0.6 mg/m2. Seventeen (12.3%) instances of neutropenia occurred with no significant difference in overall frequency or grade between groups. Thirty initially asymptomatic substage A dogs (29.4%) experienced gastrointestinal AEs. Because of the widespread use of gastrointestinal supportive care medications, statistical comparison between groups could not be performed. Seven instances of hospitalization occurred (5.0%) and the risk of hospitalization did not differ significantly between groups (P = .37). Conclusions and Clinical Importance Vincristine dosed at ≤0.6 mg/m2 does not increase the risk of hematologic AEs in dogs weighing ≤15 kg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
- Nashville Veterinary Specialists, Nashville, Tennessee, USA.
ORCID-Profile: Keira E Sztukowski, Brian D Husbands
Zitieren
APA
Sztukowski, K. E., Yaufman, Z., Cook, M. R., Aarnes, T. K., & Husbands, B. D. (2024). Vincristine-induced adverse events related to body weight in dogs treated for lymphoma. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17063
Vancouver
Sztukowski KE, Yaufman Z, Cook MR, Aarnes TK, Husbands BD. Vincristine-induced adverse events related to body weight in dogs treated for lymphoma. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17063
BibTeX
@article{Sztukowski2024,
author = {Sztukowski, Keira E and Yaufman, Zachary and Cook, Matthew R and Aarnes, Turi K and Husbands, Brian D},
title = {Vincristine-induced adverse events related to body weight in dogs treated for lymphoma},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17063}
}
EUVIMED